Online inquiry

IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13288MR)

This product GTTS-WQ13288MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PTK7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001270398.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5754
UniProt ID Q13308
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13288MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13057MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ1168MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 501
GTTS-WQ6121MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ3008MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ4770MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ4356MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ6739MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ3144MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA APT070
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW